{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:07:37Z","timestamp":1762459657847,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010878","name":"AbbVie Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00277-018-3469-4","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:02:45Z","timestamp":1535997765000},"page":"2455-2463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study"],"prefix":"10.1007","volume":"97","author":[{"given":"David","family":"Cella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"McKendrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Kudlac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abderrahim","family":"Oukessou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Zyczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"3469_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","volume":"8","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8:479\u2013491. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2011.63","journal-title":"Nat Rev Clin Oncol"},{"key":"3469_CR2","volume-title":"SEER cancer statistics review, 1975\u20132014","author":"N Howlader","year":"2017","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C et al (2017) SEER cancer statistics review, 1975\u20132014. National Cancer Institute, Bethesda, MD. \n                    https:\/\/seer.cancer.gov\/csr\/1975_2014\/\n                    \n                  . Accessed 2017 Jul 5"},{"key":"3469_CR3","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel JF, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv52\u2013iv61. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx096","journal-title":"Ann Oncol"},{"key":"3469_CR4","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","volume":"111","author":"H Ludwig","year":"2008","unstructured":"Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blad\u00e9 J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J (2008) Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 111:4039\u20134047. \n                    https:\/\/doi.org\/10.1182\/blood-2007-03-081018","journal-title":"Blood"},{"key":"3469_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, AvetLoiseau H, Hulin C, Facon T (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371:906\u2013917. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1402551","journal-title":"N Engl J Med"},{"key":"3469_CR6","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123\u20132132. \n                    https:\/\/doi.org\/10.1056\/NEJMoa070594","journal-title":"N Engl J Med"},{"key":"3469_CR7","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/leu.2009.147","volume":"23","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:2147\u20132152. \n                    https:\/\/doi.org\/10.1038\/leu.2009.147","journal-title":"Leukemia"},{"key":"3469_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:142\u2013152. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1411321","journal-title":"N Engl J Med"},{"key":"3469_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333. \n                    https:\/\/doi.org\/10.4065\/78.1.21","journal-title":"Mayo Clin Proc"},{"key":"3469_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1188\/09.ONF.209-216","volume":"36","author":"R Booker","year":"2009","unstructured":"Booker R, Olson K, Pilarski LM, Noon JP, Bahlis NJ (2009) The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma. Oncol Nurs Forum 36:209\u2013216. \n                    https:\/\/doi.org\/10.1188\/09.ONF.209-216","journal-title":"Oncol Nurs Forum"},{"key":"3469_CR11","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2011-04-347484","volume":"120","author":"I Bruns","year":"2012","unstructured":"Bruns I, Cadeddu RP, Brueckmann I, Frobel J, Geyh S, Bust S, Fischer JC, Roels F, Wilk CM, Schildberg FA, Hunerliturkoglu AN, Zilkens C, Jager M, Steidl U, Zohren F, Fenk R, Kobbe G, Brors B, Czibere A, Schroeder T, Trumpp A, Haas R (2012) Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood 120:2620\u20132630. \n                    https:\/\/doi.org\/10.1182\/blood-2011-04-347484","journal-title":"Blood"},{"key":"3469_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters S, Davies FE (2014) Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 22:417\u2013426. \n                    https:\/\/doi.org\/10.1007\/s00520-013-1991-4","journal-title":"Support Care Cancer"},{"key":"3469_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, van de Poll-Franse LV (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89:311\u2013319. \n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01831.x","journal-title":"Eur J Haematol"},{"key":"3469_CR14","first-page":"858","volume":"90","author":"A Palumbo","year":"2005","unstructured":"Palumbo A, Petrucci MT, Lauta VM, Musto P, Caravita T, Barbui AM, Nunzi M, Boccadoro M (2005) Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study. Haematologica 90:858\u2013860","journal-title":"Haematologica"},{"key":"3469_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1477-7525-8-89","volume":"8","author":"LC Doward","year":"2010","unstructured":"Doward LC, Gnanasakthy A, Baker MG (2010) Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes 8:89. \n                    https:\/\/doi.org\/10.1186\/1477-7525-8-89","journal-title":"Health Qual Life Outcomes"},{"key":"3469_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-8-79","volume":"8","author":"AK Kvam","year":"2010","unstructured":"Kvam AK, Wisloff F, Fayers PM (2010) Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. Health Qual Life Outcomes 8:79. \n                    https:\/\/doi.org\/10.1186\/1477-7525-8-79","journal-title":"Health Qual Life Outcomes"},{"unstructured":"Bristol-Myers Squibb (2017) Empliciti\u2122 (elotuzumab) prescribing information. \n                    http:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf\n                    \n                  . Accessed 2017 Jun 7","key":"3469_CR17"},{"unstructured":"European Medicines Agency (2016) Elotuzumab: summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003967\/WC500206673.pdf\n                    \n                  . Accessed 2016 May 26","key":"3469_CR18"},{"issue":"7","key":"3469_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"Sagar Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621\u2013631. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1505654\n                    \n                  ; \n                    https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1505654?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov","journal-title":"New England Journal of Medicine"},{"key":"3469_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos M-V, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P (2017) Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 178:896\u2013905. \n                    https:\/\/doi.org\/10.1111\/bjh.14787","journal-title":"Br J Haematol"},{"key":"3469_CR21","first-page":"167","volume":"102","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Mateos M-V, San MJ, Anderson K, Shpilberg O, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Belch A, Reece D, Beksac M, Mekan S, Sy O, Singhal A, Richardson P, Weisel K (2017) Phase 3 ELOQUENT-2 study: extended 4-year follow-up of elotuzumab plus lenalidomide\/dexamethasone vs lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma. Haematologica 102:167\u2013168 [S456]","journal-title":"Haematologica"},{"key":"3469_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.leu.2405016","volume":"22","author":"KC Anderson","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia 22:231\u2013239. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2405016","journal-title":"Leukemia"},{"key":"3469_CR23","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"3469_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115\u20131123. \n                    https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00930.x","journal-title":"Br J Haematol"},{"key":"3469_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2012.074534","volume":"98","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A (2013) Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica 98:784\u2013788. \n                    https:\/\/doi.org\/10.3324\/haematol.2012.074534","journal-title":"Haematologica"},{"key":"3469_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10:407\u2013415. \n                    https:\/\/doi.org\/10.1016\/0197-2456(89)90005-6","journal-title":"Control Clin Trials"},{"key":"3469_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139\u2013144. \n                    https:\/\/doi.org\/10.1200\/JCO.1998.16.1.139","journal-title":"J Clin Oncol"},{"key":"3469_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.suponc.2010.12.004","volume":"9","author":"SD Mathias","year":"2011","unstructured":"Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K (2011) Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol 9:72\u201378","journal-title":"J Support Oncol"},{"key":"3469_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-012-0175-x","volume":"22","author":"KW Wyrwich","year":"2013","unstructured":"Wyrwich KW, Norquist JM, Lenderking WR, Acaster S (2013) Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res 22:475\u2013483. \n                    https:\/\/doi.org\/10.1007\/s11136-012-0175-x","journal-title":"Qual Life Res"},{"key":"3469_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29:89\u201396. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.28.0107","journal-title":"J Clin Oncol"},{"key":"3469_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149\u2013158","journal-title":"Pain"},{"key":"3469_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11916-009-0009-x","volume":"13","author":"J Younger","year":"2009","unstructured":"Younger J, McCue R, Mackey S (2009) Pain outcomes: a brief review of instruments and techniques. Curr Pain Headache Rep 13:39\u201343. \n                    https:\/\/doi.org\/10.1007\/s11916-009-0009-x","journal-title":"Curr Pain Headache Rep"},{"key":"3469_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","volume":"61","author":"RC Serlin","year":"1995","unstructured":"Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277\u2013284","journal-title":"Pain"},{"key":"3469_CR34","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","volume":"34","author":"AK Stewart","year":"2016","unstructured":"Stewart AK, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, H\u00e1jek R, Rosi\u00f1ol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A (2016) Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol 34:3921\u20133930. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.66.9648","journal-title":"J Clin Oncol"},{"key":"3469_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ejca.2015.03.004","volume":"51","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandala M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV (2015) Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer 51:833\u2013840. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2015.03.004","journal-title":"Eur J Cancer"},{"key":"3469_CR36","doi-asserted-by":"publisher","first-page":"ii119","DOI":"10.1093\/annonc\/mdw198.04","volume":"27","author":"R Hubner","year":"2016","unstructured":"Hubner R, Cubillo A, Blanc JF, Melisi D, Von Hoff D, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong F, Siveke J (2016) 242P effects of nal-IRI (MM-398) \u00b1 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: results from NAPOLI-1. Ann Oncol 27:ii119. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw198.04","journal-title":"Ann Oncol"},{"key":"3469_CR37","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","volume":"22","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, Chen WH, Sridhara R, Farrell AT, Keegan P, Kim G, Pazdur R (2016) Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res 22:1553\u20131558. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2035","journal-title":"Clin Cancer Res"},{"key":"3469_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1634\/theoncologist.2011-S2-23","volume":"16","author":"D Cella","year":"2011","unstructured":"Cella D (2011) Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Oncologist 16:23\u201331. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2011-S2-23","journal-title":"Oncologist"},{"unstructured":"Food and Drug Administration (2009 December) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf\n                    \n                  . Accessed 2017 Apr 8","key":"3469_CR39"},{"unstructured":"National Institutes of Health (2017) PROMIS. \n                    http:\/\/www.nihpromis.org\/default\n                    \n                  . Accessed 2016 Apr 12","key":"3469_CR40"},{"key":"3469_CR41","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"LE Schnipper","year":"2015","unstructured":"Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL, American Society of Clinical Oncology (2015) American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33:2563\u20132577. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.61.6706","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3469-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3469-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3469-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T05:41:06Z","timestamp":1569130866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3469-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3469"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3469-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"26 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board or independent ethics committee approval and written informed consent from all patients for being included in the study were obtained. The study was performed in accordance with the ethical principles of the Declaration of Helsinki and in compliance with national laws.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"David Cella has served as a consultant for and\/or received research funding from AbbVie, Alexion, Astellas, Bayer, Biogen Idec, Bristol-Myers Squibb, Celgene, Clovis Oncology, Daiichi Sankyo, Eli Lilly, Evidera, Exelixis, FibroGen, Genentech, GlaxoSmithKline, Helsinn Therapeutics, Immunogen, Ipsen Pharma, Janssen, Lexicon Pharmaceuticals, Merck, Novartis, Onconova, and Pfizer. Jan McKendrick and Amber Kudlac are employees of PRMA Consulting Ltd. Antonio Palumbo has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Genmab, Janssen-Cilag, Millennium, Novartis, Onyx, and Sanofi, and served in a consulting or advisory role for Amgen, Bristol-Myers Squibb, Celgene, Genmab, Janssen-Cilag, Millennium, and Onyx. Abderrahim Oukessou, Teresa Zyczynski, and Catherine Davis are employees of Bristol-Myers Squibb. Ravi Vij has received honoraria from Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Onyx, and Takeda; served in a consulting or advisory role for Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Onyx, and Takeda; received research funding from Onyx and Takeda; and received travel, accommodations, and\/or expenses from Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Onyx, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}